Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Short term Debt (2016 - 2025)

Cytokinetics (CYTK) has disclosed Short term Debt for 12 consecutive years, with $41.2 million as the latest value for Q4 2025.

  • Quarterly Short term Debt changed N/A to $41.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $41.2 million for FY2025, N/A changed from the prior year.
  • Short term Debt for Q4 2025 was $41.2 million at Cytokinetics, up from $17.3 million in the prior quarter.
  • The five-year high for Short term Debt was $41.2 million in Q4 2025, with the low at $958000.0 in Q4 2022.
  • Average Short term Debt over 5 years is $14.1 million, with a median of $12.1 million recorded in 2024.
  • The sharpest move saw Short term Debt soared 952.19% in 2023, then rose 1.56% in 2025.
  • Over 5 years, Short term Debt stood at $16.9 million in 2021, then tumbled by 94.32% to $958000.0 in 2022, then skyrocketed by 952.19% to $10.1 million in 2023, then grew by 24.01% to $12.5 million in 2024, then surged by 229.45% to $41.2 million in 2025.
  • According to Business Quant data, Short term Debt over the past three periods came in at $41.2 million, $17.3 million, and $17.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.